Moreover, SIN1 protein levels, assessed by immunohistochemistry (IHC) on bone marrow specimens prior to treatment, correlate with adverse clinical outcomes in a cohort of AML patients treated with equivalent regimens.72 Here, MAPKAP1 is linked to acute myeloid leukemia.